Shenouda Maged's Form 4 filing
Relmada Therapeutics, Inc.RLMD · filed Sep 11, 2024
- Accession no.
- 0001213900-24-077792
- Filed
- Sep 11, 2024
- Trade date
- Sep 9-11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $149.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shenouda MagedCIK 0001658369 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2024 | Common Stock | PPurchaseAcquired | +8,194 | $2.55F2 | +$20,894.7 | 43,097 | Direct | |
| Sep 10, 2024 | Common Stock | PPurchaseAcquired | +21,118 | $2.73F3 | +$57,652.14 | 64,215 | Direct | |
| Sep 11, 2024 | Common Stock | PPurchaseAcquired | +24,120 | $2.95F4 | +$71,154 | 88,335 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Purchase prices range from $2.49 to $2.60 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
Purchase prices range from $2.70 to $2.75 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
Purchase prices range from $2.79 to $3.05 per share, inclusive.
Referenced by the price of 1 transaction in Table I.